PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.'s 2026 Annual Meeting
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
